Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB 1 cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB 1 receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB 1 receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB 2 cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB 2 receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB 2 receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB 2 receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB 2 receptor-mediated actions. 
Introduction
Alterations in the endocannabinoid (ECB) system may be involved in the aetiopathology of different neurodegenerative disorders (Maccarrone et al., 2007; Katona and Freund, 2008) . In particular, the potential therapeutic use of drugs targeting cannabinoid receptors in motor disorders, including multiple sclerosis, Parkinson's and Huntington's disease, is a subject of intense study Kreitzer and Malenka, 2007; Maccarrone et al., 2007; Maresz et al., 2007) . In Huntington's disease, neurodegeneration of striatal medium-sized spiny neurons and unbalanced neurotransmission are largely attributed to the interference of mutant huntingtin with transcriptional regulation (Cattaneo et al., 2005; Gil and Rego, 2008) . One of the earliest neurochemical changes in Huntington's disease patients is a strong depletion of neuronal CB 1 cannabinoid receptors in the basal ganglia (Richfield and Herkenham, 1994; Glass et al., 2000) . Likewise, striatal CB 1 receptors are downregulated very early in transgenic mouse models of Huntington's disease such as the R6/2 and HD94 models (Lastres-Becker et al., 2002; McCaw et al., 2004) . These observations suggest that loss of neuronal CB 1 receptors may be involved in the striatal dysfunction of the disease. The severe pre-symptomatic decline of CB 1 receptors, together with the undesirable psychoactive effects triggered by CB 1 receptor activation, prompts the search for alternative cannabinoid-based pharmacotherapies for Huntington's disease.
Non-cell autonomous neurodegeneration may play a significant role in the progression of Huntington's disease and other degenerative disorders. Overall, a dual role for microglial and astroglial cells has been proposed (Block et al., 2007; Lobsiger and Cleveland, 2007 ). An early activation of innate immune-response cells, including monocytes, macrophages and microglia, has been identified before the clinical onset of Huntington's disease patients and models of the disease (Sapp et al., 2001; Simmons et al., 2007; Tai et al., 2007; Bjorkqvist et al., 2008) . Activation of microglial cells during Huntington's disease can exert a beneficial effect in neurodegenerative lesions (e.g. trophic and clearance activity), or instead increase damage severity by secreting pro-inflammatory mediators (Block et al., 2007; Lobsiger and Cleveland, 2007) . In addition, astrocytes can contribute to Huntington's disease neurotoxicity by impaired glutamate reuptake (Shin et al., 2005) or chemokine and cytokine homoeostasis (Chou et al., 2008) . The ECB system exerts an important role in the regulation of pivotal glial cell responses such as microglial reactivity (Eljaschewitsch et al., 2006) and astroglial neurotransmitter homoeostasis (Navarrete and Araque, 2008) . A protective effect of CB 2 receptor activation in microglial cells upon inflammatory-induced CNS damage has been demonstrated in mouse models of multiple sclerosis (Maresz et al., 2007; Palazuelos et al., 2008) . However, the precise role of microglial CB 2 receptors in neurodegeneration remains uncertain (Miller and Stella, 2008) . This study was therefore undertaken to address the role of microglial CB 2 cannabinoid receptors in non-cell autonomous neurodegeneration during Huntington's disease progression. We show that genetic ablation of CB 2 receptors exacerbates Huntington's disease-like behavioural symptoms and neurochemical alterations in R6/2 mice and, likewise, increases striatal injury after excitotoxicity. In addition, administration of CB 2 receptorselective agonists reduces striatal neurodegeneration by regulating microglial activation. Taken together, our results demonstrate that CB 2 receptor activation is neuroprotective in Huntington's disease models by controlling deleterious microglial activity.
Materials and Methods
The following materials were kindly donated: CB 2 receptor knockout mice by Nancy Buckley (National Institute of Health, Bethesda, MD, USA), and anti-Iba-1 antibodies by Keiko Ohsawa (National Institute Neuroscience, Tokyo, Japan), respectively. HU-308 and other CB 2 receptor-selective ligands by Raphael Mechoulam (Hebrew University, Israel) and Pharmos (Rehovot, Israel). Other antibodies used were: mouse monoclonal anti-glial fibrillary acidic protein (GFAP) (Clon GA5, Sigma, St Louis, MO, USA), anti-NeuN (Chemicon International, Temecula, CA, USA) and anti-human CD68 (Dako, Glostrup, Denmark); rat monoclonal anti-5-bromo-2 0 -deoxyuridine (BrdU; Abcam, Cambridge, UK) and anti-mouse CD11b (clone M1/70; Becton Dickinson PharMingen, San Diego, CA, USA); rabbit polyclonal anti-CB 2 receptor (PA1-746; Affinity Bioreagents, Golden, CO, USA), anti-dopamine-and cyclic AMP-regulated phosphoprotein (DARPP32, Chemicon), anti-synaptophysin (Synaptic Systems, Gö ttingen, Germany), anti-inducible nitric oxide synthase (Becton Dickinson) and anti-lysosomal-associated membrane protein 2 (Developmental Studies Hybridoma Bank, Iowa City, IA, USA).
Animal procedures and excitotoxicity experiments
Hemizigous male mice transgenic for exon 1 of the human huntingtin gene with 140-160 CAG repeats [R6/2 mice, code B6CBA-Tg(HDexon1)62Gpb/1J] or expressing thymidine kinase under the control of the GFAP promoter [code B6.Cg-Tg(GFAP-Tk)7.1Mvs/J], as well as their corresponding wild-type (WT) littermates, were purchased from Jackson Laboratory (Ban Harbor, ME, USA). R6/1 transgenic Huntington's disease mice with a CBA/BL6 background, expressing exon 1 of the mutant huntingtin gene with $110-120 CAG repeats, were maintained and handled as described (Canals et al., 2004 Experiments of depletion of astroglial cell proliferation were performed in GFAP-TK mice to which ganciclovir (100 mg/kg, Roche Farma, Madrid, Spain) or vehicle was administered by intraperitoneal (i.p.) injection daily starting 1 day prior to excitotoxicity. Excitotoxicity was induced by intrastriatal quinolinic acid (15 nmol), administration at the following coordinates: +0.6 posterior to bregma, +1.85 medio-lateral and -2.7 dorso-ventral to dura. Increased concentrations revealed dose-dependent striatal neurodegeration (data not shown). Neurodegeneration and glial activation were investigated at different time points (4, 7 and 30 days). In pharmacological experiments, HU-308 (5 mg/kg) and additional CB 2 receptor-selective agonists (cannabinor, PRS-639 and PRS-486) were administered i.p. after excitotoxicity and thereafter daily until sacrifice. Control animals received the corresponding vehicle injections (100 ml PBS supplemented with 0.5 mg/ml defatted bovine serum albumin and 4% dimethylsulphoxide). The number of mice with clonic-tonic seizures 2 h after excitotoxicity was determined in four independent experiments in CB 2 receptor-deficient mice and WT littermates. BrdU injections (100 mg/ kg, i.p.) were performed daily from 1 h after excitotoxicity and the following three consecutive days. Anti-inflammatory treatment was performed with minocycline administration (50 mg/kg, i.p.) 1 day prior to excitotoxicity and daily thereafter until sacrifice.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed in excitotoxicity experiments the day before sacrifice at the Nuclear Magnetic Resonance Centre of Complutense University (Madrid, Spain) using a Biospec 47/40 (Bruker, Ettlingen, Germany) operating at 4.7 T, equipped with a 12 cm gradient set and using a 4 cm radio frequency surface coil. The 3D T 2 -weighted spin-echo images were acquired using a fast spin-echo sequence. Diffusion water images delineated the area of neuroinflammation evidenced as hyperintense signals which are shown as pseudocoloured images. Acquisition information and further details can be found in Supplementary material.
Immunofluorescence and confocal microscopy
Free floating coronal brain slices (30 mm) were processed as described previously . In brief, brain sections after blocking with 5% goat serum were incubated with the indicated primary antibodies (overnight incubation at 4 C) followed by secondary antibody incubation (1 h at room temperature). The appropriate mouse, rat and rabbit highly cross-adsorbed AlexaFluor 488, AlexaFluor 594 and AlexaFluor 647 secondary antibodies (Invitrogen, Carlsbad, CA, USA) were used. For double immunofluorescence with anti-Iba-1 and anti-CB 2 antibodies, the Fab fragment blocking system (Jackson Immunoresearch, Newmarket, UK) was employed following manufacturer's instructions and the appropriate controls. All immunofluorescence data were obtained in a blinded manner by independent observers in a minimum of six correlative slices from 1-in-10 series located between -0.4 and +1.6 mm to bregma. Neurodegeneration and glial activation were determined by dopamine-and cyclic AMPregulated phosphoprotein (DARPP32), CD11b, Iba-1 and GFAP immunostaining, and quantified with Image-J software. In transgenic mice and proliferation studies Iba-1, inducible nitric oxide synthase (iNOS) and BrdU-positive cells were quantified by cell counting using newCast optical fractionator (Visiopharm, Hørsholm, Denmark) and data were given as mean cell number per square millimetre. Confocal fluorescence images were acquired by using Leica TCS-SP2 software (Wetzlar, Germany) and SP2 microscope with two passes by Kalman filter and a 1024 Â 1024 collection box. In addition, fluorojade staining was also performed (according to manufacturer's instructions) and quantified as described in Supplementary material.
Real-time quantitative PCR
RNA was isolated using Trizol Reagent (Invitrogen). cDNA was obtained with Transcriptor (Roche). Real-time quantitative PCR assays were performed using the FastStart Master Mix with Rox (Roche) and probes were obtained from the Universal Probe Library Set (Roche; primer sequences can be found in Supplementary  Table S1 ). Amplifications were run in a 7900 HT-Fast Real-Time PCR System (Applied Biosystems). Each value was adjusted by using 18S RNA and b-actin levels as reference.
Human brain tissue samples
Post-mortem brain tissues from Huntington's disease (n = 6) and control donors (n = 4) were provided by the 'Banco de Tejidos para Investigació n Neurologica' (Madrid, Spain). Paraffin sections containing caudate putamen were cut into 4 mm thick sections (Benito et al., 2007) for immunohistochemical study, and non-fixed tissue was processed by Western blotting as described in Supplementary material.
Statistical analyses
Results shown represent the mean AE SEM, and the number of experiments is indicated in every case. Statistical analysis was performed by one-or two-way analysis of variance (ANOVA), as appropriate. A post hoc analysis was made by the Student Neuman-Keuls test. The occurrence of seizures in Table 1 was analysed by 2 -test.
Results
Increased CB 2 cannabinoid receptor expression and microglial activation in the striatum of Huntington's disease mouse models and patients
To address the potential involvement of CB 2 cannabinoid receptors in Huntington's disease pathogenesis, we used transgenic R6/2 mice that express exon 1 of human mutant huntingtin (Mangiarini et al., 1996) . Real-time PCR analysis of striatal extracts revealed increased CB 2 receptor transcript levels at pre-symptomatic (Week 4) and symptomatic stages (Week 8-12) of R6/2 mice (Fig. 1A) . Similarly, in R6/1 mice, a more delayed Huntington's disease murine model that expresses exon 1 of human huntingtin with fewer CAG repeats, CB 2 transcripts were increased at Week 30 (Fig. 1B) 1E and data not shown).
To further validate the findings from the transgenic mouse models, we analysed the expression of CB 2 receptors in brain samples of Huntington's disease and control patients. Huntington's disease patient samples revealed increased levels of CB 2 receptors when compared with controls ( Fig. 2A) , and this occurred in parallel with increased levels of the microglial/ macrophage markers CD11b and CD68. The cellular localization of CB 2 receptors in the caudate putamen of Huntington's disease patients was assessed by immunohistochemistry, which revealed that CB 2 expression occurred in cells with the characteristic morphology of microglia (Fig. 2B) . We next confirmed that cells (A and B) CB 2 mRNA levels were determined by real-time quantitative PCR in striatal extracts of R6/2 and R6/1 mice at the indicated ages (black bars, n = 6 each group). Transcript levels were normalized to b-actin RNA expression, referred to WT littermate levels (white bars, n = 6) and given in arbitrary units (a.u.). *P 5 0.05, **P 5 0.01 versus the WT group at the corresponding ages. (C) Representative confocal microscopy analyses of striatal sections in WT and R6/2 mice at Week 12 were performed with anti-Iba-1 (green) and anti-GFAP (red) antibodies. (D) Expression of CB 2 receptors (red) in Iba-1 (green) microglial cells was analysed in the same mice groups. Lower panels show orthogonal images of an example of CB 2 receptor expression in Iba-1 + cell. (E) Expression of CB 2 receptors (red) does not co-localize with GFAP (green) astroglial cells. Scale bars: 225 mm (C), 55 mm (D and E) and 15 mm (D, lower panels). Cc = corpus callosum; Str. = striatum. expressing CB 2 receptors in Huntington's disease correspond to CD68-positive microglia, but not to GFAP-positive astroglia ( Fig. 2C and D) .
CB 2 cannabinoid receptor deficiency exacerbates disease progression in R6/2 mice To investigate the role of CB 2 cannabinoid receptor upregulation in R6/2 mice, genetic ablation experiments were achieved by crossing R6/2 mice with CB 2 receptor-deficient mice (Buckley et al., 2000) . R6/2 mice develop a rapid course of degeneration, with motor symptoms starting at Weeks 4-6 and mortality ensuing at Weeks 14-15. In the absence of CB 2 receptors, R6/2 mice showed an aggravation of motor symptoms as determined by RotaRod analyses. Thus, a worse motor performance was observed in R6/2:CB 2 À/À mice than in R6/2:CB 2 +/+ mice at Weeks 6 and 8 (Fig. 3A) . Moreover, ablation of CB 2 receptors reduced R6/2 mice lifespan (Fig. 3B) . We then analysed in detail striatal sections from double mutant R6/2:CB 2 À/À mice in comparison with R6/2:CB 2 +/+ littermates.
Iba-1-positive cells were quantified at Week 12 in R6/2:CB 2 À/À mice, revealing increased microglial activation when compared with CB 2 receptor-expressing R6/2 littermates (Fig. 4A) . The lack of CB 2 receptors was also accompanied by increased astrogliosis (Fig. 4B) . Importantly, the exacerbated phenotype of microglial and astroglial activation that occurred in R6/2:CB 2 À/À mice was associated with a higher expression of iNOS ( Fig. 4C) and loss of the presynaptic marker synaptophysin (Cepeda et al., 2003) ( Fig. 4D) . Thus, during disease progression of transgenic R6/2 mice, microglial cell activation occurs in parallel with a concomitant upregulation of CB 2 cannabinoid receptor expression, which appears to play a protective role against striatal dysfunction.
CB 2 cannabinoid receptor-deficient mice are more sensitive to striatal neurodegeneration after excitotoxicity and have an exacerbated glial activation
In Huntington's disease, loss of medium-sized spiny neurons is accompanied by excitotoxicity, that contributes to neurodegeneration (Gil and Rego, 2008; Kalia et al., 2008) . To provide further support to the findings from CB 2 receptor genetic deletion in mutant huntingtin-expressing mice, we sought to analyse the role of CB 2 receptors in an excitotoxicity model of intrastriatal administration of the natural N-methyl-D-aspartic acid (NMDA) receptor agonist quinolinic acid. CB 2 receptor-deficient mice showed higher occurrence of clonic-tonic seizures after quinolinic acid administration (Table 1) . This higher sensitivity to excitotoxicity was reflected in an increased brain oedema volume (Fig. 5A ), higher immunoreactivity of the microglial markers CD11b and Iba-1, as well as increased GFAP + reactive astroglial cells in the lesion area when compared with their WT littermates ( Fig. 5B and C ; Supplementary Fig. 1) . A more detailed evaluation by gene expression analysis in the damaged striatum confirmed the enhanced activation of glial cells in CB 2 receptor-deficient mice, which exhibit increased transcript levels of Iba-1, GFAP and the inflammatory markers iNOS, interleukin-1b, interleukin-6 and tumor necrosis factor-. In addition, NO levels were also higher in CB 2 À/À mice than in their WT littermates ( Supplementary   Fig. 1 ). As in Huntington's disease transgenic models, CB 2 receptor transcripts were upregulated after striatal excitotoxicity and expressed by microglial but not astroglial cells (Supplementary Fig. 2A-C) . Confocal microscopy analysis indicated that the Fig. 2D and E). Quantification of medium-sized spiny neuron degeneration by DARPP32 immunofluorescence evidenced an extended neuronal loss in CB 2 receptor knockout mice 7 and 30 days after injury ( Fig. 5D and Supplementary Fig. 1 ). The observed increase in microglial and astroglial response to excitotoxicity and the severe neurodegeneration of CB 2 receptor-deficient mice appeared in concert with an exacerbated motor function impairment as revealed by RotaRod performance (Fig. 5E ). Further analysis of the lesion by BrdU labelling after striatal excitotoxicity revealed that cell proliferation was enhanced in the absence of CB 2 receptors ( Supplementary Fig. 3 ). Immunofluorescence co-localization studies showed that the majority of the proliferative cells were astroglial and microglial cells ( Supplementary Fig. 3 ).
Selective stimulation of CB 2 cannabinoid receptors attenuates glial activation and protects from striatal neuronal damage
As loss-of-function studies indicated that CB 2 receptor expression prevents neurodegeneration in Huntington's disease models, we next turned to investigate the effect of direct CB 2 receptor stimulation by using the non-psychotropic CB 2 -selective agonist HU-308 (Hanus et al., 1999) . Mice were injected with quinolinic acid, and HU-308 or vehicle was administered daily after excitotoxicity. Analysis of neurological damage by MRI evidenced that brain oedema was significantly reduced in HU-308-treated mice after excitotoxicity (Fig. 6A) . CB 2 receptor engagement decreased microglial activation and astroglial reactivity in the striatum after excitotoxicity ( Fig. 6B and C; Supplementary Fig. 4 ). This was further confirmed by real-time PCR analyses of different markers of glial activation and inflammation, as well as by the determination of NO levels ( Supplementary Fig. 4 ). The relevance of CB 2 receptor activation in HU-308-treated mice was evidenced by reduced loss of medium-sized spiny neurons as revealed by fluorojade staining and DARPP32 immunofluorescence ( Fig. 6C and D) . Furthermore, cannabinoid administration attenuated the loss of striatal GABA levels ( Fig. 6E ) and improved motor performance after excitotoxicity (Fig. 6F) . In addition to HU-308, other CB 2 -selective agonists were effective in reducing striatal neurodegeneration, GABA deficits and glial activation ( Supplementary Fig. 5 ).
Regulation of microglial activation is responsible for CB 2 cannabinoid receptor-mediated neuroprotection
To address the role of exacerbated glial activation in striatal neurodegeneration of CB 2 receptor-deficient mice after excitotoxicity, we employed the anti-inflammatory drug minocycline (Chen et al., 2000) . Minocycline treatment reduced the occurrence of excitotoxicity-induced clonic-tonic seizures in CB 2 receptor-deficient mice (Table 1) , and this protective effect was associated to better RotaRod function (Fig. 7A) . Anti-inflammatory treatment reduced the exacerbated glial activation (Fig. 7B-D) and medium-sized spiny neuronal loss ( Fig. 7B and E) of CB 2 receptor knockout mice. The protective action of the anti-inflammatory treatment against striatal excitotoxicity, together with the role of CB 2 receptors in the control of microglial neuroinflammatory processes (Miller and Stella, 2008) , supports that the beneficial effects of HU-308 rely specifically on the regulation of microglial activation by CB 2 receptors. To validate the cellular target of cannabinoid protective actions after excitotoxicity, inducible transgenic mice that allow the depletion of proliferating astroglial cells were used. Thymidine kinase activity driven under the control of the GFAP promoter (GFAP-TK) was initiated by ganciclovir administration prior to striatal excitotoxicity. Excitotoxicity affected motor coordination to the same extent in WT and GFAP-TK mice (Fig. 8A) , and in the absence of newly generated astroglia the striatal damage induced by excitotoxicity was equivalent (Fig. 8B ). In addition, pharmacological protection by HU-308 was equally effective in the presence or absence of proliferating astrocytes, with motor performance in the RotaRod analysis reaching similar levels in WT and transgenic mice (Fig. 8A) . Confocal microscopy analysis revealed that ganciclovir-treated GFAP-TK mice showed equivalent HU-308-mediated effects of glial activation ( Fig. 8C and D) , and, likewise, prevention of mediumsized spiny neuron degeneration by HU-308 was not affected by ablation of astroglial proliferation (Fig. 8E) .
Discussion
During Huntington's disease progression, the ECB system is significantly affected and, specifically, CB 1 receptors are known to be downregulated at early stages (Glass et al., 2000; McCaw et al., 2004) . The consequent loss of CB 1 receptor function may therefore contribute to unbalanced GABAergic neurotransmission (Centonze et al., 2005) , deterioration of striatal brain functions as motor coordination (Kreitzer and Malenka, 2007) and impairment of CB 1 -mediated neuroprotection (Pryce et al., 2003; Pintor et al., 2006) . Here we show that, in contrast to neuronal CB 1 receptors, microglial CB 2 receptors are induced in Huntington's disease animal models and patients, and demonstrate for the first time in a transgenic model of a neurodegenerative disease that CB 2 cannabinoid receptor ablation exacerbates microglial activation and accelerates the appearance of symptoms. Moreover, pharmacological activation of CB 2 receptors in vivo, that does not induce undesirable psychotropic actions (Mackie, 2006) , exerts a neuroprotective effect in Huntington's disease models that relies on the control of deleterious microglial activity. CB 2 receptors had been shown previously to confer neuroprotection in different animal models of acute brain toxicity and neuroinflammatory damage. Thus, CB 2 receptor-deficient mice have enhanced susceptibility to neurodegeneration in experimental autoimmune encephalomyelitis (Maresz et al., 2007; Palazuelos et al., 2008) and upon intrastriatal malonate injection (Sagredo et al., 2008) . Likewise, administration of CB 2 receptor-selective agonists is neuroprotective in models of hypoxia or excitotoxicity , experimental autoimmune encephalomyelitis Palazuelos et al., 2008) , b-amyloid peptide inoculation (Ramirez et al., 2005) and lateral amyotrophic sclerosis (Shoemaker et al., 2007) . These observations suggest that CB 2 receptor activation may be a potential therapeutic strategy for neurodegenerative disorders (Mackie, 2006; Fernandez-Ruiz et al., 2007) . The protective role of CB 2 receptor activation is mostly attributed to its ability to reduce the deleterious microglial activation (Maresz et al., 2005; Ramirez et al., 2005; Eljaschewitsch et al., 2006; Palazuelos et al., 2008) , although other studies support that CB 2 -mediated regulation of astroglial reactivity also contributes to cannabinoid neuroprotection Garcia-Ovejero et al., 2009) . In this study, the use of GFAP-TK transgenic mice cogently shows that regulation of microglial rather than astroglial activation is responsible for CB 2 receptor neuroprotective effect in Huntington's disease models.
Regulation of non-cell autonomous neurodegeneration has been proposed as an important event in the progression of different neuroinflammatory disorders (Block et al., 2007; Lobsiger and Cleveland, 2007) and, in particular, the beneficial or detrimental influence of reactive microglia and astroglia remains a matter of intense debate. Ablation of reactive astrocytes increases the severity of the damage in traumatic brain injury (Myer et al., 2006) and, likewise, reactive astroglia may be beneficial in spinal cord injury models (Okada et al., 2006) . However, conflicting findings on the role of astroglial cells have also been reported in, for example, models of motor neuron degeneration (Lepore et al., 2008; Yamanaka et al., 2008) . Regarding Huntington's disease, the role of non-cell autonomous neuronal death in the progression Quantification of microglial and astroglial activation determined by CD11b and GFAP immunoreactivity analysis, and the area loss of striatal medium-sized spiny neurons determined by DARPP32 immunoreactivity. All determinations were performed 7 days after excitotoxicity. *P50.05, **P50.01 versus their respective WT mice group; # P50.05, ## P50.01 versus their respective vehicle-treated mice.
of the disease has been recently assessed. Both brain and peripheral inflammation are observed prior to Huntington's disease onset and contribute to disease progression (Bjorkqvist et al., 2008) . Likewise, anti-inflammatory treatment with minocycline exerts a neuroprotective effect and delays mortality of R6/2 mice (Chen et al., 2000; Wang et al., 2003) , indicating a deleterious action of activated microglia on neuronal cells. In addition, astroglial cells can contribute to mutant huntingtin-induced neurodegeneration, as intranuclear aggregates impair GLT-1 and GLAST glutamate transporter expression (Shin et al., 2005) . Thus, although the contribution of microglial cells to Huntington's disease progression is highlighted from this and previous studies, the contribution of astrocytes cannot completely be ruled out (e.g. as microgliaactivated secondary sources of neurotoxic mediators). Indeed, there is a clear parallelism in microglial and astroglial responses to brain injury, which makes a very difficult task to fully elucidate the precise participation of each glial cell type in non-cell autonomous neurodegeneration, even using selective cellular depletion strategies. Our finding of increased CB 2 receptor expression in active striatal microglia of Huntington's disease patients is in agreement with the recent indications of an innate inflammatory response occurring from early stages of the disease (Bjorkqvist et al., 2008) . In addition, in Huntington's disease pre-symptomatic gene carriers, positron emission tomography studies have evidenced that microglial activation is an early pathogenic step associated to disease progression (Tai et al., 2007) . Likewise, CB 2 receptors are upregulated in reactive microglial cells in human neurodegenerative disorders such as multiple sclerosis (Benito et al., 2007; Palazuelos et al., 2008 ), Alzheimer's disease (Ramirez et al., 2005) and others (Fernandez-Ruiz et al., 2007) . The ECB-degrading enzyme fatty acid amide hydrolase constitutes after induction of striatal excitotoxicity in GFAP-TK mice and WT littermates. Treatment with HU-308 (5 mg/kg, black bars) or vehicle (white bars) was performed after excitotoxicity and then daily until sacrifice (n = 5 each group). (B) Confocal immunofluorescence images with antibodies against CD11b (red), GFAP (blue) and DARPP32 (green) was performed to assess glial cell activation and medium-sized spiny neuronal loss in the indicated mice groups. Scale bar: 150 mm. (C-E) Astroglial activation, microglial activation and striatal neurodegeneration were, respectively, determined by immunofluorescence quantification of GFAP, CD11b and DARPP32 immunoreactivity in the indicated mice groups. **P50.01 versus their respective WT mice group; # P50.05 versus their respective vehicle-treated mice.
an additional marker of neuroinflammation that labels reactive astroglia in multiple sclerosis (Benito et al., 2007) . Thus, in addition to altered CB 2 receptor levels during neuroinflammation, changes in the levels of different ECB species have been reported in the striatum and cortex of R6/2 mice and Huntington's disease patients (Maccarrone et al., 2007) . Overall, the reduction of neuronal CB 1 receptors and the upregulation of microglial CB 2 receptors support a crucial role for the ECB system in the pathogenesis of Huntington's disease. The use of drugs targeting the ECB system via CB 1 receptors aimed at restoring neurochemical alterations and palliating symptoms might constitute an interesting strategy for the management of Huntington's disease and other neurodegenerative disorders with a significant excitotoxicity component (Katona and Freund, 2008) . However, due to the early loss of CB 1 receptors during Huntington's disease, the use of CB 2 -selective agonists that avoid the undesirable psychotropic effects of CB 1 agonists may become an excellent alternative for disease control by taking advantage of the ability of these drugs to counteract neuron non-cell autonomous degeneration by active microglia.
